SVN53-67/M57-KLH Peptide Vaccine

also known as SurVaxM · SVN53-67/M57-KLH

Trials 9 · a red edge is where a trial was stopped

today NCT06202066 · Ph 2 NCT07169617 · Ph 2 NCT04978727 · Ph 1 NCT04013672 · Ph 2 NCT03879694 · Ph 1 NCT02334865 · Ph 1 NCT02455557 · Ph 2 NCT01250470 · Ph 1

20132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT04978727	Jul 2022 → Dec 2027 expected	anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, diffuse intrinsic pontine glioma +3	Children's Oncology Group	Active not recruiting	No outcome recorded
Phase 1	NCT03879694	Jun 2019 → Feb 2025	atypical carcinoid tumor, lung carcinoid tumor, pancreatic neuroendocrine tumor	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1	NCT02334865	Apr 2017 → Sep 2022 overdue	plasma cell myeloma	Roswell Park Cancer Institute	Active not recruiting	No outcome recorded
Phase 1	NCT01250470	Sep 2012 → May 2014	anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma +1	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 24 trials
Phase 2	NCT06202066	Jul 2026 → Oct 2027 expected	cancer, lung neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm	Roswell Park Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT07169617	Jul 2026 → Mar 2029 expected	lung carcinoma	National Cancer Institute (NCI)	Not yet recruiting	No outcome recorded
Phase 2	NCT04013672	Mar 2020 → Aug 2021	glioblastoma	David Peereboom	Completed	No outcome recorded
Phase 2	NCT02455557	May 2015 → Oct 2019 overdue	gliosarcoma	Roswell Park Cancer Institute	Active not recruiting	No outcome recorded
Phase not stated1 trial
—	NCT04802447	—	glioblastoma	Roswell Park Cancer Institute	No longer available	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05163080 Comparator	Nov 2021 → Aug 2024	glioblastoma	MimiVax, LLC	Unknown	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	SVN53-67/M57-KLH Peptide Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06202066 ↗
Known as	SurVaxM	“SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells” PMID 36521103 ↗ Dec 2022 5 “a survivin peptide vaccine called SurVaxM” NCT07169617 ↗ NCT04978727 ↗ NCT05163080 ↗ NCT04013672 ↗ NCT04802447 ↗
Known as	SVN53-67/M57-KLH	“This is a multicenter pilot study of SurVaxM (SVN53-67/M57-KLH) for children and young adults with progressive or relapsed medulloblastoma, high grade glioma, ependymoma and...” NCT04978727 ↗ 5 “yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the...” NCT05163080 ↗ “the SVN53-67/M57-KLH peptide in Montanide ISA 51 (Montanide ISA-51/survivin peptide vaccine) plus with GM-CSF (sargramostim).” NCT01250470 ↗ “Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart.” NCT04802447 ↗ NCT03879694 ↗ NCT02334865 ↗
Action	Deplete	“Vaccines made from survivin peptide may help the body build an effective immune response to kill tumor cells.” NCT01250470 ↗
Modality	Vaccine	“survivin peptide vaccine” NCT01250470 ↗
Route	Subcutaneous	“Patients receive Montanide ISA-51/survivin peptide vaccine subcutaneously (SC)” NCT01250470 ↗
Target	BIRC5	“Baculoviral IAP repeat-containing protein 5 vaccine antigen” CHEMBL4650424 ↗